Troy Cox

Troy Cox, the former CEO of Foundation Medicine, is Chairman of Sophia Genetics, Vice Chairman at LetsGetChecked, and Independent Board Director at Zymeworks and BioSplice as well as non-profits MassBio and Dream Foundation.

Mr. Cox was President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche valuing FMI at $5.3 billion. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion, participating in the launch of nearly half of the products from the world’s oncology leader, while accountable to help steer the Roche Genentech R&D portfolio. Before Genentech, Mr. Cox held executive and senior roles of increasingly broad accountabilities including President UCB BioPharmaceuticals, Senior Vice President Sanofi-Aventis, and diverse foundational roles at Schering-Plough.

Mr. Cox received his MBA from the University of Missouri and BBA in Finance from the University of Kentucky.